Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 1998

Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease

Danuta Rość, Ewa Zastawna, Wanda Drewniak, Arkadiusz Michalski, Maria Kotschy

Med Sci Monit 1998; 4(6): CR975-978 :: ID: 451753

Abstract

Haemostatic disturbances are observed in thyroid diseases. The fibrinolytic system reaction is suspected to be the cause. There are few data about the nature of fibrinolytic changes in the serum of patients suffering from Graves disease. The aim of our work was to study serum fibrinolytic system changes in Graves disease due to the concentration of plasminogen activators type of tissue (t-PA) and urokinase (u-PA) and plasminogen activator inhibitor type 1 (PAI-1). The study was performed on 33 patients (F/M 29/4, mean aged 35.0 years) with Graves disease and on 34 healthy volunteers(F/M 28/6, mean age: 33.7 years). Graves disease was diagnosed on the basis of clinical and laboratory evidence of thyrotoxicosis, diffuse goitre and absence of other symptoms of thyrotoxicosis. In the citric blood plasma the concentrations of tissue (t-PA) and urokinase (u-PA) plasminogen activators, and plasminogen activator inhibitor type 1 (PAI-1) antigen were determined using ELISA - test (Biopol, Sweden). The individual values of t-PA Ag and PAI-1 Ag in patients with Graves disease were ranged much wider than in control group and the concentration of antigens reached the highest values in several
cases. Mean concentrations of t-PA, u-PA and PAI-1 antigen in blood plasma of patients were significantly increased comparing to the control group. The hyperthyroid goitre in patients suffering from Graves disease seems to be the source of plasminogen activators (t-PA, u-PA) detected in the blood plasma.

Keywords: Graves Disease, fibrinolitic system, Plasminogen Activators, inhibitors

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750